JP2014515477A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515477A5 JP2014515477A5 JP2014511615A JP2014511615A JP2014515477A5 JP 2014515477 A5 JP2014515477 A5 JP 2014515477A5 JP 2014511615 A JP2014511615 A JP 2014511615A JP 2014511615 A JP2014511615 A JP 2014511615A JP 2014515477 A5 JP2014515477 A5 JP 2014515477A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- her2
- subject
- cutoff
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 125
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 125
- 238000000034 method Methods 0.000 claims description 69
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 239000012472 biological sample Substances 0.000 claims description 48
- 201000011510 cancer Diseases 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 210000004556 brain Anatomy 0.000 claims description 28
- 206010027476 Metastases Diseases 0.000 claims description 27
- 230000009401 metastasis Effects 0.000 claims description 25
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims description 11
- 239000000556 agonist Substances 0.000 claims description 10
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010059282 Metastases to central nervous system Diseases 0.000 claims description 5
- 230000008499 blood brain barrier function Effects 0.000 claims description 5
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 101150054472 HER2 gene Proteins 0.000 claims description 4
- 108700020302 erbB-2 Genes Proteins 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 230000004544 DNA amplification Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 229940126586 small molecule drug Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 101710106089 Protein cutoff Proteins 0.000 claims 38
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 description 5
- 239000000710 homodimer Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161488028P | 2011-05-19 | 2011-05-19 | |
| US61/488,028 | 2011-05-19 | ||
| PCT/US2012/038867 WO2012159115A1 (en) | 2011-05-19 | 2012-05-21 | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017093074A Division JP6626037B2 (ja) | 2011-05-19 | 2017-05-09 | 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515477A JP2014515477A (ja) | 2014-06-30 |
| JP2014515477A5 true JP2014515477A5 (cg-RX-API-DMAC7.html) | 2015-05-14 |
| JP6468838B2 JP6468838B2 (ja) | 2019-02-13 |
Family
ID=47175183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511615A Active JP6468838B2 (ja) | 2011-05-19 | 2012-05-21 | 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 |
| JP2017093074A Active JP6626037B2 (ja) | 2011-05-19 | 2017-05-09 | 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017093074A Active JP6626037B2 (ja) | 2011-05-19 | 2017-05-09 | 癌患者の生存可能性を決定するためおよび癌患者における転移可能性を予測するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20120295259A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3124975B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6468838B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2835284C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2615265T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG194609A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012159115A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11401344B2 (en) | 2008-12-01 | 2022-08-02 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
| US20120295259A1 (en) | 2011-05-19 | 2012-11-22 | Laboratory Corporation Of America Holdings | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients |
| US10451614B2 (en) | 2016-03-15 | 2019-10-22 | Laboratory Corporation Of America Holdings | Methods of assessing protein interactions between cells |
| EP3615067A1 (en) * | 2017-04-28 | 2020-03-04 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4318846A (en) | 1979-09-07 | 1982-03-09 | Syva Company | Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers |
| US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
| US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| JP2681061B2 (ja) | 1988-06-08 | 1997-11-19 | ロンドン・ダイアグノスティック・インコーポレーテッド | 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ |
| US4997928A (en) | 1988-09-15 | 1991-03-05 | E. I. Du Pont De Nemours And Company | Fluorescent reagents for the preparation of 5'-tagged oligonucleotides |
| US5654442A (en) | 1989-11-14 | 1997-08-05 | The Perkin-Elmer Corporation | 4,7-dichlorofluorescein dyes as molecular probes |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| ATE146508T1 (de) | 1990-11-02 | 1997-01-15 | Zeneca Ltd | Polysubstituierte phthalocyanine |
| JP2758730B2 (ja) | 1991-04-25 | 1998-05-28 | 三菱電機株式会社 | 放電励起パルスレーザ発振装置 |
| US6251581B1 (en) | 1991-05-22 | 2001-06-26 | Dade Behring Marburg Gmbh | Assay method utilizing induced luminescence |
| US5578498A (en) | 1991-05-22 | 1996-11-26 | Behringwerke Ag | Metal chelate containing compositions for use in chemiluminescent assays |
| US5340716A (en) | 1991-06-20 | 1994-08-23 | Snytex (U.S.A.) Inc. | Assay method utilizing photoactivated chemiluminescent label |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| WO1993021230A1 (en) | 1992-04-10 | 1993-10-28 | Dana-Farber Cancer Institute, Inc. | Activation-state-specific phosphoprotein immunodetection |
| JP3464798B2 (ja) | 1992-07-31 | 2003-11-10 | デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 光活性化化学発光基質 |
| US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
| US5986076A (en) | 1994-05-11 | 1999-11-16 | Trustees Of Boston University | Photocleavable agents and conjugates for the detection and isolation of biomolecules |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US5945526A (en) | 1996-05-03 | 1999-08-31 | Perkin-Elmer Corporation | Energy transfer dyes with enhanced fluorescence |
| US5763602A (en) | 1996-10-01 | 1998-06-09 | Li; Ying-Syi | Methods of syntheses of phthalocyanine compounds |
| US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| US6001673A (en) | 1999-02-11 | 1999-12-14 | Ericsson Inc. | Methods for packaging integrated circuit devices including cavities adjacent active regions |
| US6627400B1 (en) | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
| US6673550B2 (en) | 1999-04-30 | 2004-01-06 | Aclara Biosciences, Inc. | Electrophoretic tag reagents comprising fluorescent compounds |
| US20030235832A1 (en) | 2000-06-21 | 2003-12-25 | Ahmed Chenna | Multiplexed analysis by chromatographic separation of molecular tags |
| US6191278B1 (en) | 1999-11-03 | 2001-02-20 | Pe Corporation | Water-soluble rhodamine dyes and conjugates thereof |
| US6372907B1 (en) | 1999-11-03 | 2002-04-16 | Apptera Corporation | Water-soluble rhodamine dye peptide conjugates |
| US6346384B1 (en) | 2000-03-27 | 2002-02-12 | Dade Behring Inc. | Real-time monitoring of PCR using LOCI |
| US20030170734A1 (en) | 2000-04-28 | 2003-09-11 | Stephen Williams | Multiplexed assays using electrophoretically separated molecular tags |
| EP1305632B1 (en) | 2000-05-04 | 2011-07-27 | Siemens Healthcare Diagnostics Products GmbH | Methods for detection of multiple analytes |
| WO2003051669A1 (en) | 2001-12-18 | 2003-06-26 | Aclara Biosciences, Inc. | Photoactivation device and method |
| EP1478765A4 (en) | 2002-03-05 | 2006-12-06 | Aclara Biosciences Inc | MULTIPLEX ANALYSIS USING MEMBRANE-FIXED SENSITIZERS |
| US7402397B2 (en) | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| ATE442589T1 (de) | 2002-07-25 | 2009-09-15 | Aclara Biosciences Inc | Nachweis der rezeptoroligomerisierung |
| US7402398B2 (en) | 2003-07-17 | 2008-07-22 | Monogram Biosciences, Inc. | Measuring receptor homodimerization |
| WO2005011607A2 (en) * | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
| WO2005037071A2 (en) | 2003-10-14 | 2005-04-28 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| WO2006086730A2 (en) * | 2005-02-09 | 2006-08-17 | Genentech, Inc. | Inhibiting her2 shedding with matrix metalloprotease antagonists |
| WO2009086197A1 (en) | 2007-12-20 | 2009-07-09 | Monogram Biosciences, Inc. | Her-2 diagnostic methods |
| EP2438442B1 (en) * | 2008-12-01 | 2017-08-09 | Laboratory Corporation of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| US20120295259A1 (en) | 2011-05-19 | 2012-11-22 | Laboratory Corporation Of America Holdings | Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients |
| US20100233732A1 (en) | 2009-01-15 | 2010-09-16 | Laboratory Corporation Of America Holdings | Methods of Determining Patient Response By Measurement of HER-2 Expression |
| BRPI1007321A2 (en) * | 2009-01-15 | 2018-07-10 | Laboratory Corporation Of America Holdings | methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody. |
| NZ596468A (en) * | 2009-05-14 | 2013-11-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| ES2363669B1 (es) * | 2009-06-10 | 2012-08-09 | Fundacio Privada Institut D'investigacio Biomedica De Bellvitge (Idibell) | Metodo para determinar el riesgo de desarrollar metastasis cerebral y un kit para llevar a cabo dicho procedimiento |
| JP5795311B2 (ja) * | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
-
2012
- 2012-05-21 US US13/476,735 patent/US20120295259A1/en not_active Abandoned
- 2012-05-21 CA CA2835284A patent/CA2835284C/en active Active
- 2012-05-21 EP EP16189315.1A patent/EP3124975B1/en active Active
- 2012-05-21 EP EP12785543.5A patent/EP2710379B1/en active Active
- 2012-05-21 JP JP2014511615A patent/JP6468838B2/ja active Active
- 2012-05-21 ES ES12785543.5T patent/ES2615265T3/es active Active
- 2012-05-21 WO PCT/US2012/038867 patent/WO2012159115A1/en not_active Ceased
- 2012-05-21 SG SG2013078977A patent/SG194609A1/en unknown
- 2012-05-21 ES ES16189315T patent/ES2701929T3/es active Active
-
2017
- 2017-05-09 JP JP2017093074A patent/JP6626037B2/ja active Active
-
2018
- 2018-10-22 US US16/166,816 patent/US11579148B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hermine et al. | Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network | |
| US9945870B2 (en) | Methods for determining responsiveness to an anti-CD47 agent | |
| Mendell et al. | Clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (HER3) monoclonal antibody, in patients with advanced non-small cell lung cancer | |
| Samuel et al. | Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers | |
| Gruel et al. | Biological dosimetry by automated dicentric scoring in a simulated emergency | |
| JP2023529026A5 (cg-RX-API-DMAC7.html) | ||
| JP2018502828A5 (cg-RX-API-DMAC7.html) | ||
| Singarayer et al. | A systematic review and meta-analysis of the diagnostic performance of BRAF V600E immunohistochemistry in thyroid histopathology | |
| Polivka Jr et al. | Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? | |
| Dreyling et al. | The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive? | |
| Zhao et al. | CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: a meta-analysis | |
| JP2011515497A5 (cg-RX-API-DMAC7.html) | ||
| JP2016536330A5 (cg-RX-API-DMAC7.html) | ||
| KR102067327B1 (ko) | 최적의 암 치료를 위한 Her2 단백질 정량 | |
| JP2015530868A5 (cg-RX-API-DMAC7.html) | ||
| WO2018075869A1 (en) | Method of predicting graft versus host disease | |
| JP2018508532A5 (cg-RX-API-DMAC7.html) | ||
| Massard et al. | RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study | |
| JP2018532978A (ja) | 最適な癌療法のためのFR−αおよびGARTタンパク質の定量 | |
| JP2014524571A (ja) | がん治療用予測因子 | |
| WO2018150031A1 (en) | Method of detecting cancer or cancer cells | |
| Khadela et al. | Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects | |
| CN113174439B (zh) | 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用 | |
| Zhong et al. | Senescence-related genes analysis in breast cancer reveals the immune microenvironment and implications for immunotherapy | |
| JP2020524794A (ja) | 最適な癌療法のためのslfn11タンパク質の定量 |